₹200 Cr Profit but Margins Slip: Pfizer Ltd Q4 Earnings Show Mixed Performance

By- Shahzad Ahmad 

May 13, 2026 at 10:38 AM (GST)

Key Highlights

• Net Profit falls 39.6% YoY to ₹200 crore
• Revenue rises 6.3% YoY to ₹629.2 crore
• EBITDA grows 3.7% YoY to ₹236 crore
• Operating Margin slips to 37.5% from 38.4%
• Final Dividend of ₹75/share recommended for FY26

  Pfizer Ltd reported a mixed set of earnings for the fourth quarter of FY26, with revenue and operating profit registering year-on-year growth, while net profit witnessed a sharp decline due to margin pressure and higher costs.

  The pharmaceutical major posted a net profit of ₹200 crore for the March quarter, marking a 39.6% decline from ₹311 crore reported in the same period last year.

  Despite the drop in bottom-line earnings, revenue from operations rose 6.3% to ₹629.2 crore compared with ₹592 crore in the year-ago quarter, reflecting steady demand across its key therapy and vaccine portfolio.

  EBITDA increased 3.7% year-on-year to ₹236 crore versus ₹228 crore in Q4FY25. However, operating margins softened to 37.5% from 38.4% a year earlier, indicating pressure on profitability despite higher sales.
   

  The board of directors recommended a final dividend of ₹75 per equity share (750% on face value of ₹10) for FY26. Subject to shareholder approval at the upcoming AGM, the dividend will be paid on or after August 4, 2026. The record date for eligible shareholders has been fixed as July 17, 2026.

  Investor sentiment remained cautious ahead of the earnings release, with shares of Pfizer Ltd ending over 3% lower at ₹4,728.90 on the NSE before the results announcement.

  The latest quarterly numbers come after the company delivered a strong December quarter performance, driven by healthy demand across core therapeutic segments and improved operating leverage. During that period, margins had expanded significantly due to stronger sales momentum and cost efficiencies.

  As the Indian arm of global pharma giant Pfizer, the company operates across multiple healthcare segments including anti-infectives, cardiology, immunology, vaccines, and pain management.